Diana Bradford

7PUBLICATIONS
69CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsCancer geneticsAvionics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Apr 17, 2026
Selpercatinib and the Crossover Conundrum: Potential Impact of Postprogression Therapies on Overall Survival.

|Jan 14, 2025
FDA Approval Summary: Tovorafenib for Relapsed or Refractory BRAF-Altered Pediatric Low-Grade Glioma.

Sonia Singh, Diana Bradford, Somak Chatterjee

|Jun 14, 2024
FDA Approval Summary: Repotrectinib for Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer.

Michael I Barbato, Diana Bradford, Yi Ren

|Feb 15, 2024
Considering Functional Outcomes as Efficacy Endpoints in Pediatric Low-Grade Glioma Clinical Trials: An FDA Educational Symposium.

Jason Fangusaro, Robert A Avery, Michael J Fisher

|Aug 25, 2023
FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth Spectrum.

Sonia Singh, Diana Bradford, Xiaoxue Li

|Aug 23, 2023
FDA Approval Summary: Dabrafenib in Combination with Trametinib for BRAFV600E Mutation-Positive Low-Grade Glioma.

Michael I Barbato, Jeannette Nashed, Diana Bradford

Pageof 2

Frequent Collaborators

6 joint publications

Harpreet Singh

5 joint publications

Pallavi S Mishra-Kalyani

5 joint publications

Richard Pazdur

4 joint publications

Martha Donoghue